AVTE Annual Cash & Cash Equivalents
$23.49 M
+$1.09 M+4.88%
31 December 2023
Summary:
As of January 22, 2025, AVTE annual cash & cash equivalents is $23.49 million, with the most recent change of +$1.09 million (+4.88%) on December 31, 2023. During the last 3 years, it has risen by +$18.92 million (+413.69%). AVTE annual cash & cash equivalents is now -56.66% below its all-time high of $54.20 million, reached on December 31, 2021.AVTE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTE Quarterly Cash And Cash Equivalents
$31.11 M
+$46.00 K+0.15%
30 September 2024
Summary:
As of January 22, 2025, AVTE quarterly cash and cash equivalents is $31.11 million, with the most recent change of +$46.00 thousand (+0.15%) on September 30, 2024. Over the past year, it has increased by +$7.62 million (+32.45%). AVTE quarterly cash and cash equivalents is now -82.80% below its all-time high of $180.88 million, reached on September 30, 2021.AVTE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTE Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.9% | +32.5% |
| 3 y3 years | +413.7% | +32.5% |
| 5 y5 years | +568.5% | +32.5% |
AVTE Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.7% | +4.9% | -48.9% | +241.1% |
| 5 y | 5-year | -56.7% | +568.5% | -82.8% | +580.4% |
| alltime | all time | -56.7% | +568.5% | -82.8% | +580.4% |
Aerovate Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $31.11 M(+0.1%) |
| June 2024 | - | $31.07 M(+240.6%) |
| Mar 2024 | - | $9.12 M(-61.2%) |
| Dec 2023 | $23.49 M(+4.9%) | $23.49 M(-27.0%) |
| Sept 2023 | - | $32.18 M(-47.2%) |
| June 2023 | - | $60.90 M(+129.2%) |
| Mar 2023 | - | $26.57 M(+18.6%) |
| Dec 2022 | $22.40 M | $22.40 M(-0.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $22.42 M(-18.3%) |
| June 2022 | - | $27.46 M(-2.4%) |
| Mar 2022 | - | $28.14 M(-48.1%) |
| Dec 2021 | $54.20 M(+1085.2%) | $54.20 M(-70.0%) |
| Sept 2021 | - | $180.88 M(+205.8%) |
| June 2021 | - | $59.15 M(+584.5%) |
| Mar 2021 | - | $8.64 M(+89.0%) |
| Dec 2020 | $4.57 M(+30.1%) | $4.57 M |
| Dec 2019 | $3.51 M | - |
FAQ
- What is Aerovate Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual cash & cash equivalents year-on-year change?
- What is Aerovate Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Aerovate Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AVTE is $23.49 M
What is the all time high annual cash & cash equivalents for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual cash & cash equivalents is $54.20 M
What is Aerovate Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AVTE annual cash & cash equivalents has changed by +$1.09 M (+4.88%)
What is Aerovate Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AVTE is $31.11 M
What is the all time high quarterly cash and cash equivalents for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly cash and cash equivalents is $180.88 M
What is Aerovate Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AVTE quarterly cash and cash equivalents has changed by +$7.62 M (+32.45%)